Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TFPI | P10646 | 1/20 | 0.69 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.55 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.55 |
| ▸ | VIPR1 | P32241 | 2/20 | 0.55 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.55 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.55 |
| ▸ | PTH1R | Q03431 | 1/20 | 0.54 |
| ▸ | VIPR2 | P41587 | 1/20 | 0.54 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.53 |
| ▸ | NPY4R | P50391 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29387068 | 1.00 | TFPI (0.69) | TFPIKEAP1KISS1RVIPR1NMUR2 | |
| Acetic Acid SCHEMBL29533494 | 0.99 | TFPI (0.69) | TFPIKEAP1KISS1RVIPR1NMUR2 | |
| SCHEMBL29405667 | 0.92 | TFPI (0.66) | TFPIKEAP1OPRM1OPRD1OPRK1 | |
| SCHEMBL30863947 | 0.92 | TFPI (0.66) | TFPIOPRM1OPRD1OPRK1NPY4R | |
| SCHEMBL30842195 | 0.91 | TFPI (0.65) | TFPIKEAP1VIPR1PTH1RVIPR2 | |
| SCHEMBL30436216 | 0.90 | TFPI (0.79) | TFPIVIPR1VIPR2 | |
| SCHEMBL29548324 | 0.90 | TFPI (0.63) | TFPIKISS1RNPY4R | |
| SCHEMBL30601869 | 0.89 | TFPI (0.79) | TFPIVIPR1VIPR2 | |
| SCHEMBL30842196 | 0.89 | OPRM1 (0.64) | TFPIKISS1ROPRM1OPRD1OPRK1 | |
| SCHEMBL29368760 | 0.89 | TFPI (0.61) | TFPIKISS1RNPY4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025111482-A1 | COMPLEXING AGENT SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS AT LOW STOICHIOMETRIC RATIOS | BEXSON BIOMEDICAL, INC. (US) | 2025-05-30 | — | — | WO | claimed |
| US-20240327520-A1 | METHODS AND COMPOSITIONS FOR PKC-DELTA INHIBITION AND CANCER IMMUNOTHERAPY | THE UNIVERSITY OF CHICAGO (US) | 2024-10-03 | — | — | US | claimed |
| WO-2023081934-A1 | METHODS AND COMPOSITIONS FOR PKC-DELTA INHIBITION AND CANCER IMMUNOTHERAPY | THE UNIVERSITY OF CHICAGO (US) | 2023-05-11 | — | — | WO | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| US-20250304916-A1 | METHODS AND COMPOSITIONS FOR GENERATING VASCULAR LEPTOMENINGEAL CELLS | TRAILHEAD BIOSYSTEMS INC (US) | 2025-10-02 | — | — | US | disclosed |
| EP-3891158-B1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250186253-A1 | DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| EP-4566672-A2 | METHODS FOR THE TREATMENT OF OCULAR DISEASE IN HUMAN SUBJECTS | Clearside Biomedical Inc. (US) | 2025-06-11 | — | — | EP | disclosed |
| US-11559428-B2 | Apparatus and methods for ocular injection | CLEARSIDE BIOMEDICAL, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-2887982-B1 | APPARATUS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE BIOMEDICAL INC (US) | 2022-11-23 | — | — | EP | disclosed |
| US-11504431-B2 | Formulations for the suprachoroidal space of an eye and methods | EMORY UNIVERSITY (US) | 2022-11-22 | — | — | US | disclosed |
| WO-2022221720-A1 | ANTIBODY DRUG CONJUGATES AND METHODS FOR MAKING THEREOF | NOVARTIS AG (CH) | 2022-10-20 | — | — | WO | disclosed |
| US-11446398-B2 | Regulated biocircuit systems | OBSIDIAN THERAPEUTICS, INC. (US) | 2022-09-20 | — | — | US | disclosed |
| US-20220280341-A1 | APPARATUS AND METHODS FOR DRUG DELIVERY USING MICRONEEDLES | CLEARSIDE ROYALTY LLC | 2022-09-08 | — | — | US | disclosed |
| US-20220280386-A1 | METHODS AND APPARATUS FOR EXTRACTING FLUID FROM CONTAINER | CLEARSIDE BIOMEDICAL, INC. | 2022-09-08 | — | — | US | disclosed |
| WO-2022076938-A1 | APPARATUS AND METHODS OF RETINAL INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
| CN-110177527-B | Device and method for adjusting insertion depth of needle for medicament delivery | 科尼尔赛德生物医学公司 | 2022-02-01 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327520-A1 | METHODS AND COMPOSITIONS FOR PKC-DELTA INHIBITION AND CANCER IMMUNOTHERAPY | PRKCB, PRKCG, PRKCA | TFPI 2329/4885KEAP1 2424/4885KISS1R 4815/4885 |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | TFPI 986/4885KEAP1 4720/4885KISS1R 406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.